Currently, there are more than 30 million dementia patients worldwide (1). More than half of dementia is caused by Alzheimer disease (AD), which consists of both familial and sporadic forms. Familial AD is caused by mutations in the amyloid precursor protein (APP) (2) and presenilin genes (3). Both mutations cause overproduction of amyloid-β (Aβ), particularly its longer form, Aβ42, which is more prone to aggregate. It should be noted that familial AD accounts for a small proportion of all AD cases. On the other hand, sporadic cases comprise more than 95% of AD, and emerging evidence suggests that diabetes is a nongenetic risk factor for sporadic AD (4). While diabetes increases AD 1.5–2-fold, the mechanism whereby diabetes enhances AD risk has not been elucidated. As 285 million people battle diabetes worldwide against the backdrop of an aging society (5), understanding the relationship between AD and diabetes is of extreme importance.

Interestingly, several clinical reports have suggested that AD patients also have glucose intolerance, suggesting a bidirectional relationship between the two conditions (6,7). Supporting this idea are data from animal models such as APP + ob/ob mice showing that AD aggravates the diabetic phenotype (8,9). Although further evidence is still required to confirm this concept, it is intriguing to investigate the mechanisms whereby AD affects the diabetic phenotype. Several possibilities can be hypothesized. First, central control of peripheral glucose metabolism may be compromised in AD (10). Second, plasma Aβ may mediate peripheral insulin resistance. Third, Aβ accumulation occurs in the pancreas (11) and skeletal muscle (12). There are also in vitro data suggesting a molecular link between Aβ and insulin. These data indicate that insulin modulates Aβ level by increasing its secretion (13) or by inhibiting insulin-degrading enzyme–mediated Aβ degradation (14).

It has been reported that plasma Aβ level is increased after glucose loading in an AD model (15). In humans, although the magnitude of changes is much smaller than in AD transgenic mice, the changes in plasma Aβ levels after oral glucose loading are nonetheless different between AD and non-AD patients (16). It is also reported that insulin administration induces a greater increase in plasma Aβ level in AD patients compared with nondemented control subjects (17). Together, this evidence suggests that one of the possible mechanisms by which AD aggravates the diabetic phenotype might be attributable to plasma Aβ. Zhang et al. (18) previously reported that APP/presenilin 1 (PS1) transgenic AD mice with increased plasma Aβ40/42 levels have impaired glucose/insulin tolerance and hepatic insulin signaling as well as activation of the JAK2/STAT3/SOCS1 pathway. In this issue of Diabetes, Zhang et al. (19) extended this line of investigation by examining the role of plasma Aβ in insulin resistance in vivo (Fig. 1).

Zhang et al. (19) demonstrate that plasma Aβ induces hepatic insulin resistance in vivo via JAK2. They demonstrate that injection of Aβ42 upregulated fasting blood glucose level and impaired insulin tolerance and hepatic insulin signaling in mice. Consistent with the findings from their previous work, Aβ42 induced SOCS-1 upregulation and JAK2/STAT3 activation in mouse liver. In this study, Zhang et al. also tried neutralization of Aβ in APP/PS1 to investigate the role of plasma Aβ in insulin resistance. They found that neutralization of Aβ by anti-Aβ antibodies inhibited hepatic JAK2/STAT3/SOCS1 signaling in APP/PS1 mice. These findings raise the possibility that inhibition of Aβ signaling could be a new strategy for addressing insulin resistance and diabetes. Furthermore, the investigators showed that knockdown of hepatic JAK2 by adenovirus inhibited JAK2/STAT3/SOCS-1 signaling and improved insulin sensitivity in APP/PS1 mice. The JAK/STAT/SOCS pathway was initially identified as being downstream of inflammatory cytokines (20), by which inflammation aggravates insulin resistance in the peripheral system. Even though no receptor or mediator of Aβ has yet been consistently identified, the JAK/STAT/SOCS pathway is one of the candidates that Aβ could affect directly or indirectly. It is also noteworthy that Aβ causes insulin resistance in culture neurons (21) and the central nervous system (CNS) in vivo (8). Therefore, the detailed pathway from Aβ to systemic insulin resistance through JAK/STAT/SOCS might also provide insights into the role of Aβ in the CNS.

The most important finding of this study is that neutralization of Aβ downregulated fasting blood glucose level and improved insulin sensitivity in AD model mice. Whether AD aggravates diabetes in clinical settings in humans requires more intensive observational studies. It should be noted that one weakness of this study was the relatively high concentration of injected Aβ. When Aβ was injected intraperitoneally, plasma concentrations were 400 and 1,500 pg/mL, or nearly 80 and 300 pmol/L. However, plasma Aβ42 level in humans is usually less than these values (22). Moreover, as intraperitoneal injection could directly affect hepatic cells in addition to the effect through vessels, a more in-depth discussion on the role of plasma Aβ on hepatic insulin sensitivity might be helpful. Another important question is whether plasma Aβ plays a role in the peripheral system such as in insulin resistance in humans, although it undoubtedly has a pathological role in the CNS. If these questions could be addressed clearly, prevention of these two devastating diseases might be strengthened by interrupting this vicious cycle.

It is still unclear whether plasma Aβ could be a noninvasive biomarker for AD (22). Because the measurement of plasma Aβ level is simple and straightforward, its clinical significance in the potential relationship between AD and diabetes warrants further investigation. Importantly, since it is known that the plasma Aβ level could be affected by various molecules and physiological conditions, other common diseases affecting insulin sensitivity such as hypertension, obesity, and dyslipidemia might have influence on plasma Aβ level and, by extension, its utility as a marker for AD. Continuing progress in pharmacotherapy to neutralize Aβ by vaccine or low molecular weight drugs might answer questions regarding the interaction between AD and diabetes in humans in the very near future.

See accompanying original article, p. 1159.

No potential conflicts of interest relevant to this article were reported.

1.
Dartigues
JF
.
Alzheimer’s disease: a global challenge for the 21st century
.
Lancet Neurol
2009
;
8
:
1082
1083
[PubMed]
2.
Goate
A
,
Chartier-Harlin
MC
,
Mullan
M
, et al
.
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease
.
Nature
1991
;
349
:
704
706
[PubMed]
3.
Sherrington
R
,
Rogaev
EI
,
Liang
Y
, et al
.
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease
.
Nature
1995
;
375
:
754
760
[PubMed]
4.
Ott
A
,
Stolk
RP
,
van Harskamp
F
,
Pols
HA
,
Hofman
A
,
Breteler
MM
.
Diabetes mellitus and the risk of dementia: The Rotterdam Study
.
Neurology
1999
;
53
:
1937
1942
[PubMed]
5.
Type 2 diabetes epidemic: a global education
.
Lancet
2009
;
374
:
1654
[PubMed]
6.
Bucht
G
,
Adolfsson
R
,
Lithner
F
,
Winblad
B
.
Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type
.
Acta Med Scand
1983
;
213
:
387
392
[PubMed]
7.
Meneilly
GS
,
Hill
A
.
Alterations in glucose metabolism in patients with Alzheimer’s disease
.
J Am Geriatr Soc
1993
;
41
:
710
714
[PubMed]
8.
Takeda
S
,
Sato
N
,
Uchio-Yamada
K
, et al
.
Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes
.
Proc Natl Acad Sci USA
2010
;
107
:
7036
7041
[PubMed]
9.
Sato
N
,
Takeda
S
,
Uchio-Yamada
K
, et al
.
Role of insulin signaling in the interaction between Alzheimer disease and diabetes mellitus: a missing link to therapeutic potential
.
Curr Aging Sci
2011
;
4
:
118
127
[PubMed]
10.
van de Nes
JA
,
Kamphorst
W
,
Ravid
R
,
Swaab
DF
.
Comparison of beta-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer’s disease patients: amorphic plaques and cytoskeletal changes occur independently
.
Acta Neuropathol
1998
;
96
:
129
138
[PubMed]
11.
Miklossy
J
,
Qing
H
,
Radenovic
A
, et al
.
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes
.
Neurobiol Aging
2008;31:1503–1515
[PubMed]
12.
Roher
AE
,
Esh
CL
,
Kokjohn
TA
, et al
.
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease
.
Alzheimers Dement
2009
;
5
:
18
29
[PubMed]
13.
Gasparini
L
,
Gouras
GK
,
Wang
R
, et al
.
Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling
.
J Neurosci
2001
;
21
:
2561
2570
[PubMed]
14.
Qiu
WQ
,
Walsh
DM
,
Ye
Z
, et al
.
Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation
.
J Biol Chem
1998
;
273
:
32730
32738
[PubMed]
15.
Takeda
S
,
Sato
N
,
Uchio-Yamada
K
, et al
.
Elevation of plasma beta-amyloid level by glucose loading in Alzheimer mouse models
.
Biochem Biophys Res Commun
2009
;
385
:
193
197
[PubMed]
16.
Takeda
S
,
Sato
N
,
Uchio-Yamada
K
, et al
.
Oral glucose loading modulates plasma β-amyloid level in Alzheimer’s disease patients: potential diagnostic method for Alzheimer’s disease
.
Dement Geriatr Cogn Disord
2012
;
34
:
25
30
[PubMed]
17.
Kulstad
JJ
,
Green
PS
,
Cook
DG
, et al
.
Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease
.
Neurology
2006
;
66
:
1506
1510
[PubMed]
18.
Zhang
Y
,
Zhou
B
,
Zhang
F
, et al
.
Amyloid-β induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 2012;61:1434–1443
19.
Zhang
Y
,
Zhou
B
,
Deng
B
, et al
.
Amyloid-β induces hepatic insulin resistance in vivo via JAK2. Diabetes 2013;62:1159–1166
20.
Hirano
T
,
Ishihara
K
,
Hibi
M
.
Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors
.
Oncogene
2000
;
19
:
2548
2556
21.
Tokutake
T
,
Kasuga
K
,
Yajima
R
, et al
.
Hyperphosphorylation of tau induced by naturally secreted amyloid-β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3β signaling pathway
.
J Biol Chem
2012
;
287
:
35222
35233
[PubMed]
22.
Iwatsubo
T
.
Amyloid beta protein in plasma as a diagnostic marker for Alzheimer’s disease
.
Neurobiol Aging
1998
;
19
:
161
163
[PubMed]
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.